Breckenridge Pharmaceutical Initiates Nationwide Duloxetine Recall Over Nitrosamine Impurity
Breckenridge Pharmaceutical has initiated a nationwide Class II recall of Duloxetine Delayed-Release Capsules due to N-nitroso-duloxetine, an NDSRI, exceeding interim limits. This voluntary action impacts 14,863 bottles, signaling critical CGMP deviations. Procurement and regulatory teams must assess supply chain vulnerabilities and enhance impurity testing protocols to mitigate future risks.
Immediate Impact: Breckenridge Pharmaceutical Initiates Nationwide Duloxetine Recall
Breckenridge Pharmaceutical, Inc., based in Berkeley Heights, NJ, has initiated a voluntary Class II recall (D-0308-2025) of its Duloxetine Delayed-Release Capsules, USP, 30 mg. This critical action, initiated on March 26, 2025, impacts a significant quantity: 14,863 bottles distributed nationwide across the United States. The affected product, specifically NDC 51991-747-10 from Lot 240909C with an expiration date of March 31, 2027, is manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles, Spain, and distributed by Breckenridge. For procurement directors, this recall necessitates an immediate assessment of inventory levels and current supply contracts for Duloxetine. Any reliance on this specific lot or manufacturer for the generic Duloxetine Hydrochloride (ANDA203088) must be identified, and contingency plans for sourcing must be activated to prevent supply disruptions. Regulatory affairs teams should note the Class II classification, indicating the potential for temporary or reversible adverse health consequences, which still warrants prompt action to protect patient safety and market stability.
Unpacking the CGMP Deviation: Nitrosamine Impurity Risks in Duloxetine
The fundamental reason for this recall is a critical CGMP deviation: the presence of N-nitroso-duloxetine, a Nitrosamine Drug Substance Related Impurity (NDSRI), exceeding the recommended interim limit. This finding underscores the ongoing regulatory focus by the FDA on nitrosamine contamination across the pharmaceutical industry. For quality assurance and regulatory compliance heads, this event highlights the imperative for robust impurity profiling and control strategies, particularly for active pharmaceutical ingredients (APIs) and finished drug products. The identification of N-nitroso-duloxetine above interim limits signals a potential failure in either raw material control, manufacturing processes, or stability testing protocols at the manufacturing site, Towa Pharmaceutical Europe, S.L. Businesses must ensure their supplier qualification processes include rigorous scrutiny of nitrosamine risk assessments, mitigation plans, and analytical testing capabilities. This incident reinforces that even voluntary recalls due to CGMP deviations can lead to significant market disruption and reputational damage if not proactively managed through stringent quality systems.
Supply Chain Resilience: Mitigating Duloxetine Sourcing Risks
The nationwide distribution of the recalled Duloxetine Delayed-Release Capsules, 30 mg, poses an immediate challenge for supply chain VPs and procurement teams. With 14,863 bottles of a single lot (240909C) affected, the market for this specific dosage and formulation of Duloxetine Hydrochloride (UNII: 9044SC542W) could experience localized or temporary shortages. While the recall is firm-initiated and ongoing, the ripple effect on downstream formulators and healthcare providers who rely on Breckenridge Pharmaceutical's supply chain for ANDA203088 is tangible. Businesses must diversify their supplier base for critical generic medications like Duloxetine, a widely used antidepressant. Relying on a single manufacturer or distributor, such as Towa Pharmaceutical Europe, S.L. or Breckenridge Pharmaceutical, Inc., for key molecules exposes organizations to significant risk when such quality issues arise. Proactive identification and qualification of alternative suppliers, including those in different geographical regions, are paramount to building resilient supply chains and minimizing the commercial impact of such regulatory actions.
Broader Regulatory Landscape: Heightened Scrutiny on Pharmaceutical Quality
This Breckenridge Pharmaceutical recall of Duloxetine due to NDSRI contamination is not an isolated incident but rather indicative of a broader trend of heightened regulatory scrutiny by the FDA on pharmaceutical quality and safety. Recent parallel events, such as Essential Wellness Pharma's Class II recall for sterility assurance failures or the FDA hearing impacting Amgen's Tavneos market future, underscore a persistent focus on CGMP compliance and product integrity across the industry. For regulatory affairs heads and business development executives, this signals an environment where compliance failures, even if voluntary and firm-initiated, carry significant commercial implications. The FDA's ongoing vigilance means that companies must not only meet current regulatory standards but also anticipate evolving expectations, particularly concerning emerging contaminants like nitrosamines. Investing in robust quality management systems, comprehensive risk assessments, and continuous monitoring of manufacturing processes is no longer just a compliance exercise but a strategic imperative to maintain market access and competitive advantage.
Strategic Response: Ensuring Compliance and Product Availability Post-Recall
For Breckenridge Pharmaceutical, Inc., and its manufacturing partner Towa Pharmaceutical Europe, S.L., the ongoing recall status necessitates a comprehensive remediation plan to address the root cause of the N-nitroso-duloxetine contamination. This will likely involve a thorough investigation into the manufacturing process, raw material sourcing, and stability data for Duloxetine Delayed-Release Capsules. For procurement directors evaluating Breckenridge as a supplier, or considering Towa Pharmaceutical Europe, S.L. as a potential API source, enhanced due diligence will be critical. This includes requesting detailed corrective and preventive action (CAPA) plans, reviewing updated nitrosamine risk assessments, and potentially conducting on-site audits to verify compliance. The market demands not only product availability but also unwavering confidence in quality. Companies must proactively engage with their suppliers to understand their nitrosamine control strategies and ensure that all products, especially those under ANDA203088, meet the highest safety and quality standards to prevent similar disruptions and maintain patient trust.